| DrugRepV_7536 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7537 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7538 | Digoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7539 | Digoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7540 | Digitoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7541 | Digitoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7564 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7565 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7566 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7567 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7571 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7572 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7581 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7582 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7588 | Ivacaftor | Respiratory System | Cystic fibrosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7589 | Ivacaftor | Respiratory System | Cystic fibrosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7591 | Hydroxyprogesterone | Genito Urinary System And Sex Hormones | Reduces the rate of recurrent preterm birth | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7592 | Hydroxyprogesterone | Genito Urinary System And Sex Hormones | Reduces the rate of recurrent preterm birth | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7600 | Abemaciclib | Antineoplastic And Immunomodulating Agents | Cancer | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7601 | Abemaciclib | Antineoplastic And Immunomodulating Agents | Cancer | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7604 | Eltrombopag | Blood and Blood Forming Organs | Idiopathic thrombocytopenic purpura (ITP) | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7605 | Eltrombopag | Blood and Blood Forming Organs | Idiopathic thrombocytopenic purpura (ITP) | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7606 | Gilteritinib | Antineoplastic and Immunomodulating Agents | Relapsed or refractory acute myeloid leukaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7607 | Gilteritinib | Antineoplastic and Immunomodulating Agents | Relapsed or refractory acute myeloid leukaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7610 | Camostat | Blood and Blood Forming Organs | Pancreatitis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7611 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7612 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7622 | Anidulafungin | Antiinfectives For Systemic Use | Invasive candidiasis/candidaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7623 | Anidulafungin | Antiinfectives For Systemic Use | Invasive candidiasis/candidaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7625 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7626 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7639 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2019 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7640 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2019 | NA | Immunofluorescence | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7641 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7642 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7710 | AMG-2674 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7711 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7712 | Clofazimine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32707573 |
| DrugRepV_7713 | DS-6930 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7714 | Elopiprazole | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7715 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7716 | KW 8232 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7717 | N-tert-Butylisoquine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7718 | R 82913 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7719 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7720 | SDZ-62-434 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7721 | SL-11128 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7722 | YH-1238 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7723 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7724 | AMG-2674 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7725 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7726 | Clofazimine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32707573 |
| DrugRepV_7727 | Elopiprazole | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7728 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7729 | MLN-3897 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7730 | KW 8232 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7731 | N-tert-Butylisoquine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7732 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7733 | SDZ-62-434 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7734 | SL-11128 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7735 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7736 | 8-(2-Chlorostyryl)caffeine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7737 | AMG-2674 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7738 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7739 | Elopiprazole | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7740 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7741 | KW 8232 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7742 | MLN-3897 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7743 | N-tert-Butylisoquine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7744 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7745 | SDZ-62-434 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7746 | YH-1238 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7747 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7748 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Investigational | 32707573 |
| DrugRepV_7749 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7750 | ONO 5334 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7751 | Z LVG CHN2 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7752 | MDL 28170 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7753 | SL-11128 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7754 | Clofazimine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32707573 |
| DrugRepV_7755 | DS-6930 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7756 | R 82913 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7757 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7758 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7759 | MLN-3897 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7760 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7761 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Investigational | 32707573 |
| DrugRepV_7762 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7763 | ONO 5334 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7764 | Z LVG CHN2 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7765 | MDL 28170 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7766 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Investigational | 32707573 |
| DrugRepV_7767 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7768 | ONO 5334 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7769 | Z LVG CHN2 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7770 | MDL 28170 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |